Aliskiren

Hospital Pharmacy

Volumn 42, Issue 8, 2007, Pages 737-746

  Cada, Dennis J ^a   Levien, Terri ^a   Baker, Danial E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN I; ANGIOTENSIN II; ATENOLOL; CATECHOLAMINE; CELECOXIB; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; LOSARTAN; METFORMIN; MEVINOLIN; PLACEBO; RAMIPRIL; RASAGILINE; RENIN; SODIUM; TEKTURNA; UNCLASSIFIED DRUG; VALSARTAN; WARFARIN;

ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MONITORING; DRUG POTENTIATION; DRUG STABILITY; DRUG STORAGE; DRUG WITHDRAWAL; HEART FAILURE; HEART RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT INDICATION;

EID: 34548099711     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4208-737     Document Type: Review

References (36)

1. Tekturna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
2. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. HTN. 2005;46:569-576.
3. Feldman DL, Jin L, Miserindino-Moltini R, Xuan H, Luft FC, Muller DN. Aliskiren, a human renin inhibitor induces persistent renoprotection comparable to ACE inhibition in double transgenic rats (DTGR) [abstract]. Am J Hypertens. 2005;18(suppl 1):A230.
4. White WB. Novel therapy in the management of HTN: preliminary experience with renin inhibitors [abstract]. Am J Hypertens. 2005;18(suppl 1):A266-A267.
5. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens. 2005;23:417-426.
6. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. HTN. 2002;39:e1-e8.
7. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-3133.
8. Pool J, Gradman A, Kolloch R, et al. Aliskiren, a novel renin inhibitor, provides long-term suppression of the renin system, when used alone or in combination with hydrochlorothiazide in the treatment of HTN [abstract]. Eur Heart J. 2006;27(suppl 1):119.
9. Gradman AH, Flack JM, Arora V, et al. Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: a pooled analysis of 1612 patients with HTN [abstract]. Circulation. 2006;114(suppl):773.
10. Vaidyanathan S, Limoges D, Yeh C, Dieterich H. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers [abstract]. Clin Pharmacol Ther. 2006;79(suppl):P64.
11. Zhao C, Vaidyanathan S, Yeh CM, Maboudian M, Dieterich HA. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2006;45:1125-1134.
12. Vaidyanathan S, Warren V, Yeh CM, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol. 2007;47:192-200.
13. Vaidyanathan S, Jermany J, Yeh CM, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2006;62:690-698.
14. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of HTN, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract. 2006;60:1343-1356.
15. Vaidyanathan S, Jermany J, Yeh CM, Bizot MN, Camisasca RP. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects [abstract]. Am J Hypertens. 2005;18(suppl 1):A75-A76.
16. Vaidyanathan S, Zhao C, Yeh C, Dieterich H. Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes [abstract]. Clin Pharmacol Ther. 2006;79(suppl):P12.
17. Vaidyanathan S, Reynolds C, Yeh CM, et. al. Pharmacokinetics, safety and tolerability of the novel oral direct renin inhibitor aliskiren in elderly subjects [abstract]. J Clin Pharmacol. 2006;46:1072.
18. Vaidyanathan S, Bigler H, Yeh CM, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics of the oral direct renin inhibitor aliskiren in patients with renal impairment [abstract]. J Clin Pharmacol. 2006;46:1072.
19. Weir M, Bush C, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy and safety of the oral renin inhibitor aliskiren in patients with HTN: a pooled analysis [abstract]. Eur Heart J. 2006;27(suppl 1):299.
20. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20.
21. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential HTN with an oral renin inhibitor, aliskiren. HTN. 2003;42:1137-1143.
22. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
23. Oh BH, Chung J, Khan M, Keefe D, Satlin A. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy, and placebo-like tolerability in patients with HTN [abstract]. J Am Coll Cardiol. 2006;47(suppl A):370A-371A.
24. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217-226.
25. Sica D, Gradman A, Lederballe O, Meyers M, Cai J, Keefe DL. Aliskiren, a novel renin inhibitor, is well tolerated and has sustained BP-lowering effects alone or in combination with HCTZ during long-term (52 weeks) treatment of HTN [abstract]. Eur Heart J. 2006;27(suppl 1):121.
26. Munger MA, Drummond W, Essop MR, Maboudian M, Khan M, Keefe DL. Aliskiren as add-on to amlodipine provides significant additional blood pressure lowering without increased oedema associated with doubling the amlodipine dose [abstract]. Eur Heart J. 2006;27(suppl 1):117.
27. O'Brien E, Stanton A, Jensen C, Nussberger J. Aliskiren, an orally effective renin inhibitor, suppresses plasma renin activity and improves blood pressure lowering in combination with irbesartan in patients with HTN [abstract]. Circulation. 2005;112(suppl 2):U521.
28. O'Brien E, Barton J, Nussberger J, et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. HTN. 2007;49:276-284.
29. Uresin Y, Taylor A, Kilo C, et al. Aliskiren, a novel renin inhibitor, has greater BP lowering than ramipril and additional BP lowering when combined with ramipril in patients with diabetes and HTN [abstract]. J Hypertens. 2006;24(suppl 4):S82.
30. Tschoepe D, Taylor A, Kilo C, et al. Aliskiren, alone and in combination with ramipril, significantly lowers blood pressure and plasma renin activity in patients with diabetes and HTN, regardless of the degree of glycaemic control [abstract]. Diabetologia. 2006;49(suppl 1):136.
31. Seed A, Gardner R, McMurray J, et al. First experience with an orally active renin inhibitor (aliskiren) in patients with chronic heart failure. Heart. 2003;89:A57.
32. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet. 2006;368:1449-1456.
33. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther. 2005;43:527-535.
34. Dieterich H, Kemp C, Vaidyanathan S, Yeh C. Pharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers [abstract]. Clin Pharmacol Ther. 2006;79(suppl):P12.
35. Dieterich H, Kemp C, Vaidyanathan S, Yeh C. Aliskiren, the first in a new class of orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers [abstract]. Clin Pharmacol Ther. 2006;79(suppl):P64.
36. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol. 2004;58:433-436.